Aberrant activation of the Wnt/β-catenin signaling pathway promotes the progression of osteoarthritis (OA). We previously reported that R-spondin 2 (Rspo2), an activator of the Wnt/β-catenin signaling, facilitates differentiation of proliferating chondrocytes into hypertrophic chondrocytes by enhancing Wnt/β-catenin signaling in endochondral ossification. However, the role of Rspo2 in OA remains elusive. Here, we showed that the amounts of Rspo2 protein in synovial fluid were increased in OA patients. We searched for a preapproved drug that suppresses Rspo2-induced Wnt/β-catenin signaling in chondrogenic cells and reduces joint pathology in a rat model of OA. In Rspo2-treated ATDC5 cells, mianserin, a tetracyclic antidepressant, inhibited Wnt/β-catenin signaling, increased proteoglycan production, and upregulated chondrogenic marker genes. Mianserin suppressed Rspo2-induced accumulation of β-catenin and phosphorylation of Lrp6. We identified that mianserin blocked binding of Rspo2 to its receptor Lgr5. We also observed that intraarticular administration of mianserin suppressed β-catenin accumulation and prevented OA progression in a rat model of OA. We conclude that mianserin suppresses abnormally activated Wnt/β-catenin signaling in OA by inhibiting binding of Rspo2 to Lgr5.
www.nature.com/scientificreports www.nature.com/scientificreports/ Rspo2 is an important factor for regulating cell proliferation and differentiation, as well as tissue development. Single nucleotide variations in RSPO2 are associated with proliferative bone and soft tissue diseases in human 20, 21 . We recently reported that Rspo2 activates Wnt/β-catenin signaling and reduces expressions of chondrogenic marker genes of Sox9 (sex-determining region Y-Box 9; a master gene for chondrocyte differentiation), Col2a1 (collagen type II α1), and Acan, which subsequently facilitates differentiation of proliferating chondrocytes into hypertrophic chondrocytes in the growth cartilage 22 . Hypertrophic differentiation of articular chondrocytes is similarly observed in human OA and animal OA models 23, 24 . Excessive Wnt/β-catenin signaling activity facilitates hypertrophic differentiation of articular chondrocytes, which, in turn, induces cartilage-degrading metalloproteinase expression and subsequent OA aggravation 7, 25 . However, involvement of Rspo2 in OA remains to be elucidated. Here, we observed that Rspo2 is increased in synovial fluid in OA patients. We next searched for a drug to antagonize the effect of Rspo2 using the drug repositioning strategy, in which a drug currently used to treat a specific disease is applied to another disease 26, 27 . We found that mianserin, a tetracyclic antidepressant, suppressed Rspo2-induced activation of Wnt/β-catenin signaling in chondrocytes, which subsequently ameliorated loss of proteoglycans and increased expressions of Sox9, Col2a1, and Acan. Mianserin exerted its anti-Rspo2 effect by directly blocking binding of Rspo2 to Lgr5. In a rat model of OA, intraarticular administration of mianserin reduced accumulation of β-catenin in articular chondrocytes and prevented OA progression.
Results and Discussion
Rspo2 in synovial fluid in patients with knee OA increases with increasing OA severities. We first confirmed that glycosaminoglycans (GAG), which are degradation products of GAG chains in cartilage proteoglycans 28 , were increased in synovial fluid with increasing OA severities that was evaluated by the Kellgren-Lawrence (KL) radiographic grading system 29 (Fig. 1A-C ). We next observed that intraarticular Rspo2 gradually increased with worsening of OA up to KL grade 3, but was decreased at KL grade 4. This may represent that the number of intraarticular Rspo2-producing and other cells is reduced at KL grade 4. Alternatively, the increase of Rspo2 is associated with only initiation and progression of OA ( Fig. 1D -F, Supplementary Table S1 ). The amounts of Rspo2 were much higher in female patients than male patients ( Fig. 1D ,E). In contrast to Rspo2, the amounts of Wnt antagonists including dickkopf (DKK)-1, DKK-2, and sclerostin in synovial fluid are inversely correlated with OA severity [30] [31] [32] .
Mianserin inhibits Rspo2-induced activation of Wnt/β-catenin signaling and increases the amounts of Rspo2-reduced ECM in human chondrosarcoma (HCS)-2/8 cells. We next attempted
to identify a clinically applicable drug that inhibits Rspo2-induced activation of Wnt/β-catenin signaling and OA progression. We quantified Wnt/β-catenin signaling activity using the TOPFlash luciferase reporter assay in the presence of 1,271 FDA-approved drugs in HCS-2/8 cells, and searched for a drug that suppresses Rspo2-activated Wnt/β-catenin signaling. Recombinant human Rspo2 (rhRspo2) alone does not activate Wnt/β-catenin signaling in HCS-2/8 cells, but enhances the signaling in the presence of a low dose of recombinant human Wnt3a (rhWnt3a) ( Supplementary Fig. S1A ) 17 . We thus performed drug screening with 120 ng/ml rhRspo2 and 20 ng/ ml rhWnt3a, and found that a tetracyclic antidepressants (TeCA), mianserin, that is an antagonist or inverse agonist of the histaminergic H 1 receptor, serotoninergic 5-HT 1-7 receptors, and α 2 -adrenergic receptor, suppressed the TOPFlash reporter activity in a dose-dependent manner ( Fig. 2A ). Interestingly, mianserin did not reduce Wnt/β-catenin signaling activated by rhWnt3a alone (Fig. 2B ). We observed that 120 ng/ml rhRspo2 and 20 ng/ ml rhWnt3a upregulated mRNA expression of Wnt/β-catenin-responsive AXIN2 33 in HCS-2/8 cells, and that mianserin attenuated the upregulation of AXIN2 ( Supplementary Fig. S1B ). We also observed similar tendencies in two other Wnt/β-catenin-responsive genes of CCND1 34 and MYC 35 in HCS-2/8 cells ( Supplementary  Fig. S1B -D). We next tested two other TeCAs: maprotiline, the first TeCA ever to be developed 36 , and mirtazapine, one of analogues for mianserin 37 . In contrast to mianserin, neither maprotiline nor mirtazapine suppressed the TOPFlash reporter activity at 10 μM (1.000 ± 0.272 and 1.018 ± 0.289, mean and SD, n = 3, respectively). Taken together, mianserin inhibited the TOPFlash reporter activity via Rspo2, and the effect is unlikely to be associated with its tetracyclic structure.
We evaluated the effects of mianserin on ECM production in mouse chondrogenic ATDC5 cells, which produce high levels of ECM when Wnt/β-catenin signaling is not activated 22 . Quantitative analysis of Alcian blue staining revealed that mianserin ameliorated rhRspo2-induced, but not rhWnt3a-induced, reduction of proteoglycans ( Fig. 2C,D) . We also confirmed that mianserin mitigated Rpos2-induced upregulation of Axin2 ( Fig. 2E ), as well as Rspo2-induced downregulation of Sox9, Col2a1, and Acan (Fig. 2F ,G,H). These results indicate that mianserin mitigates Rspo2-induced suppression of ECM production. As far as we know, the effect of mianserin on Rspo2 has not been reported previously. We previously reported that another antidepressant, fluoxetine, ameliorates cartilage degradation in OA by inhibiting Wnt/β-catenin signaling. The putative target of fluoxetine, however, is likely to be a degradation complex including β-catenin or its downstream signaling, and not Rspo2 10 .
Mianserin reduces Rspo2-induced β-catenin accumulation and Lrp6 phosphorylation, and blocks binding of Rspo2 to Lgr5. We first confirmed that Rnf43/Znrf3 mRNAs, Lgr4-6 mRNAs, and Lgr5 protein were expressed in differentiated ATDC5 cells ( Supplementary Fig. S2A,B ). Rspo2 did not alter mRNA expressions of Rnf43/Znrf3 (Fig. 3A,B) and Lgr4/5/6 in 48 h in differentiated ATDC5 cells ( Fig. 3C-E ). In contrast, as in HEK293 cells 38 , Rspo2 increased the expressions of Lrp6, Lrp5, Frizzled6 (Fzd6), and β-catenin proteins in 48 h in differentiated ATDC5 cells ( Fig. 3F and Supplementary Fig. S2C ), which was likely to be initiated by increased phosphorylation at Ser1490 of Lrp6 39 in 1.5 h ( Fig. 3G ). Mianserin suppressed rhRspo2-mediated increases of Lrp6, Lrp5, Fzd6, and β-catenin proteins, as well as Lrp6 phosphorylation, in differentiated ATDC5 cells and in HEK293 cells (Fig. 3F ,G and Supplementary Fig. S2C,D) . These observations prompted us to hypothesize that the target of mianserin is either upstream or on the cell membrane. Rspos activate Wnt/β-catenin www.nature.com/scientificreports www.nature.com/scientificreports/ signaling by forming a complex with the extracellular domains of both Lgr4/5/6 and RNF43/ZNRF3 17, 18 . As Lgr5 was highly expressed in both OA cartilage (OAC) cells stated below and ATDC5 cells ( Supplementary Fig. S2A,B) , we evaluated the effect of mianserin on the binding of human Rspo2 to Lgr5 on the surface of HEK293 cells. We found that mianserin suppressed binding of Rspo2 to Lgr5 in a dose-dependent manner ( Fig. 4H ). We similarly evaluated the effect of mianserin on the binding of human Rspo2 to RNF43 on the surface of HEK293 cells, but observed no effect ( Fig. 4H ). Thus, mianserin directly suppresses binding of Rspo2 to Lgr5, and subsequently attenuates Lrp6 expression and β-catenin accumulation in chondrocytes.
Mianserin inhibits β-catenin accumulation in chondrogenic cells in OA cartilage and mitigates articular cartilage degradation in a rat OA model. To examine the effects of mianserin on OA cartilage
(OAC), we isolated OA cells from OA patients undergoing total knee replacement surgery. We first confirmed that Rnf43/Znrf3 mRNAs, Lgr4-6 mRNAs, and Lgr5 protein were expressed in OAC cells, as we observed in ATDC5 cells ( Supplementary Fig. S2A,B ). Cell viability assay showed that less than 100 µM of mianserin had no toxicity on OAC cells ( Supplementary Fig. S3A ). Immunoblotting showed that mianserin decreased rhRspo2-induced accumulation of β-catenin ( Supplementary Fig. S3B ,C), indicating that mianserin suppresses Wnt/β-catenin signaling in human OAC cells without overt toxicity. Supplementary Table S1. www.nature.com/scientificreports www.nature.com/scientificreports/ We also examined the effects of mianserin on articular chondrocytes in a rat OA model. Rats were intraarticularly injected with 50 µl phosphate-buffered saline (PBS, control) or 50 µM mianserin once weekly for 8 weeks after OA induction by destabilization of the medial meniscus (DMM) surgery. At 8 weeks after surgery, mianserin improved Safranin-O staining on the articular surfaces and preserved articular cartilage structures in DMM-operated knees (Fig. 4A,B ). We also observed that mianserin reduced the cellular and nuclear intensities of β-catenin ( Fig. 4C-E) , and the ratio of β-catenin-positive cells (Fig. 4F ).
Thus, intraarticular injection of mianserin suppresses Wnt/β-catenin signaling in articular chondrocytes and ameliorates OA progression in a rat OA model (Fig. 4G ). As the loss-of-function of β-catenin in cartilage also www.nature.com/scientificreports www.nature.com/scientificreports/ Representative Western blots and intensities of phosphorylated Lrp6 normalized for those of total Lrp6 and also for untreated cells are shown. Mean and SD are indicated (n = 3). *P < 0.05 by one-way ANOVA followed by www.nature.com/scientificreports www.nature.com/scientificreports/ causes osteoarthritic changes by increasing apoptotic cells 40 , a certain level of Wnt/β-catenin signaling is required for articular cartilage 41 . Optimization of administration protocols, scrutinized analysis of adverse effects, and examination of an additive effect of concomitant treatment for a rat OA model need to be performed before mianserin is applied to human OA patients. Evaluation of the suppressive effect of long-term mianserin in depressed patients on OA development in epidemiological studies will also help elucidate the effect of mianserin on OA patients. In addition to OA, dysregulation of Rspo2 is also reported in several cancers 4, 18, 42 and in proliferative diseases of bone and soft tissue 20, 43 . We expect that mianserin is a potential repositioned drug that ameliorates human diseases associated with Rspo2-mediated abnormal activation of Wnt/β-catenin signaling.
Materials and Methods
Quantification of Rspo2 amounts in patient synovial fluid with knee OA. All studies involving human synovial fluid were performed in accordance with the protocol in Institutional Review Board of Nagoya University Hospital (The protocol No. 2015-0239-2) and approved by the Ethical Review Committee of the Nagoya University Graduate School of Medicine. After an appropriate written informed consent was obtained at Nagoya University Hospital, synovial fluid samples were acquired from 52 patients with knee OA (16 males and 36 females; ages, 36-93 years; and mean age, 74.6 years) with needle puncture at the outpatient clinic when the patients had hydrarthrosis. The diagnosis of knee OA was based on the criteria of the American Rheumatism Association 44 . Two authors independently evaluated plain knee radiographs and severity of knee OA was decided using the Kellgren-Lawrence (KL) radiographic grading system (grade 1, 14 patients; grade 2, 17 patients; grade 3, 13 patients; and grade 4, 8 patients) 29 . Each KL grade is characterized as follows: grade 1, doubtful OA with minimal osteophytes of dubious importance; grade 2, mild OA with definite osteophytes but unimpaired joint space; grade 3, moderate OA with moderate osteophytes and definite joint space narrowing; and grade 4, severe OA with considerably impaired joint space and sclerosis of subchondral bone 45 .
All patients had knee effusion caused by synovitis and underwent an arthrocentesis of the knee under aseptic condition. After centrifugation at 18,000 × g for 20 min at 4 °C to remove cells and other debris, concentrations of Rspo2 and total protein in the collected synovial fluid samples were quantified. Concentrations of Rspo2 were determined by the Human R-Spondin 2 (RSPO2) ELISA Kit (MyBioSource) according to the manufacturer's instructions and using PowerScan4 (DS Pharma Biomedical) to measure absorbance at 450 nm. Concentrations of total protein were quantified by the Pierce 660 nm Protein Assay Kit (Pierce Biotechnology). We also evaluated concentrations of glycosaminoglycans (GAG) in synovial fluid by a spectrophotometric dye binding assay using 1,2, dimethylmethylene blue (DMMB; Santa Cruz Biotechnology) 46 . A positive correlation between GAG concentration in synovial fluid and KL grade was demonstrated in a previous report 28 . 
Screening of 1,271 FDA-approved drugs with

Immunoblotting for β-catenin, total Lrp6, and phosphorylated Lrp6 in differentiated ATDC5 cells and human OAC cells. Differentiated ATDC5 cells and OAC cells were treated with 0-20 μM mianserin
in the presence of 200 ng/ml rhRspo2 for the indicated times. Cells were harvested with ice-cold RIPA Lysis Buffer (Santa Cruz Biotechnology) with 0.1 mM dithiothreitol, 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin and phosphatase inhibitors (PhosSTOP; Sigma-Aldrich). Whole-cell lysates were separated on SDS-PAGE and transferred to a nitrocellulose membrane. Expression levels of β-catenin, β-actin, Lrp6, phosphorylated Lrp6, Lrp5, Frizzled 6 and Gapdh were determined using antibodies against β-catenin (dilution 1:1,000, 610154, Becton Dickinson), β-actin (1:250, sc47778, Santa Cruz Biotechnology), Lrp6 (1:500, sc15399, Santa Cruz Biotechnology), phospho-Lrp6 at Ser1490 (1:1,000, #2568, Cell Signaling Technology), Lrp5 (1:1,000, #5731, Cell Signaling Technology), Frizzled 6 (1:1,000, #5158, Cell Signaling Technology), and Gapdh (1:1,000, sc-47724, Santa Cruz Biotechnology), respectively. Signal intensities were normalized either to the β-actin or the total Lrp6 level. Three independent experiments were performed, and quantified using the NIH ImageJ software. www.nature.com/scientificreports www.nature.com/scientificreports/ www.nature.com/scientificreports www.nature.com/scientificreports/ Tadasuke Tsukiyama at Hokkaido University, Japan 48 . We previously reported the full-length human LGR5 (BC099650) cDNA in pcDNA3.1 49 . The C-terminal-deleted human RSPO2 cDNA (amino acids 1-218) and the C-terminal of rat Agrn cDNA (amino acids 1141-1937 of M64780.1) were cloned into APtag-5 (GenHunter Corp.) at the HindIII and SnaBI sites to make the myc-and-alkaline phosphatase-tagged Rspo2 (Rspo2-mycAP) and the myc-and-alkaline phosphatase-tagged Agrn (Agrn-mycAP) as described previously 49 .
Preparation of
HEK293 cells were transfected with Rspo2-mycAP to make Rspo2-CM. Rspo2-mycAP and Agrn-mycAP in the CM were concentrated ~100-fold using Amicon Ultra-4 filters (Merck Millipore) for the cell surface binding assay. HEK293 cells were transfected with 3 μg RNF43/pcDNA3-HA, 5 μg Lgr5/pcDNA3.1, or 5 µg empty pcDNA3.1 using Lipofectamine 2000 (Thermo Fisher Scientific). Cells were incubated for 24 h with concentrated CM containing either Rspo2-mycAP or Agrn-mycAP then placed on ice for 1.5 h. Cells were washed with HABH buffer (0.5 mg/ml BSA, 0.1% NaN 3 , and 20 mM HEPES (pH 7.0) in Hank's balanced salt solution), and then fixed in 60% acetone for 10 min on ice followed by 4% paraformaldehyde in 20 mM HEPES (pH 7.0) in Hank's balanced salt solution for 10 min on ice. Fixed cells were washed once with 20 mM HEPES (pH 7.0) and 150 mM NaCl, incubated at 65 °C for 30 min, washed once with 0.1 M Tris-HCl (pH 8.0), and lysed with 0.1% Triton-X in Tris-HCl (pH 8.0). AP activity in the lysed solutions was measured using LabAssay ALP (Wako Pure Chemical Industries Ltd.) to quantify bound Rspo2-mycAP or Agrn-mycAP. Agrn-mycAP was used to confirm that it did not bind to the cell surface of RNF43-transfected or Lgr5-transfected HEK293 cells (data not shown).
In vivo surgical induction of OA and intraarticular administration of mianserin. All animal exper-
iments were performed in accordance with the recommendations in the Regulations on Animal Experiments in Nagoya University and approved by the Animal Care and Use Committee of the Nagoya University Graduate School of Medicine (The protocol No. 2017-29469). Ten-week-old male Wistar/ST rats were anesthetized with isoflurane and their right knee joints were induced to OA by surgical destabilization of the medial meniscus (DMM) 50 . Briefly, the knee joint was aseptically exposed with a medial capsular incision and the medial menisco-tibial ligament was resected to destabilize the medial meniscus. Sham surgery was performed on the contralateral left knee with incisions of the skin and joint capsule. Rats were randomly divided into PBS and mianserin groups (n = 3 each), and 50 µl PBS (control group) and 50 μM mianserin in 50 µl PBS (mianserin group) was intraarticularly injected into both knees once weekly, respectively. At 8 weeks after surgery, the rats were sacrificed and their knee joints were fixed overnight in 4% paraformaldehyde at 4 °C, decalcified, and embedded in paraffin. We made multiple sections around the middle portion of the medial femoral condyle (i.e. the weight-baring area) of each sample. A single section crossing the narrowest interarticular portion was stained with Safranin O and Fast-green. OA progressions were graded according to the modified Mankin histologic score 51 on both tibial and femoral sides of articular cartilage.
The modified Mankin histological score is the sum of seven parameters. These include the articular cartilage structure (grades 0-11); tidemark duplication (grades 0-3); Safranin O staining (grades 0-8); fibrocartilage (grades 0-2); chondrocyte clones in uncalcified cartilage (grades 0-2); hypertrophic chondrocytes in calcified cartilage (grades 0-2); and subchondral bone (grades 0-2). Using a single well-cut and well-stained sagittal section crossing the narrowest interarticular portion in the medial compartment of the knee joint, the grades of OA were scored by a single blinded observer and averaged in each group of mice.
For immunofluorescence staining, the paraffin-embedded sections were deparaffinized and rehydrated. They were unmasked with 10 mM sodium citrate buffer (pH 6.0) at 90 °C for 15 min and incubated in 3% H 2 O 2 for 15 min to inactivate endogenous peroxidases. They were then treated with a blocking buffer containing 5% goat serum in TBS-T for 1 h at room temperature and incubated with anti-β-catenin antibody (dilution 1:100; Cell Signaling Technology) at 4 °C overnight. The sections were then washed with TBS-T and incubated with Alexa 488-conjugated goat anti-rabbit IgG (dilution 1:500; Invitrogen) at room temperature for 1 h. The specimens were then mounted in VectaShield containing 2 µg/ml diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc.) and visualized with an A1Rsi microscope (Nikon Corp.). The average signal intensities of β-catenin in cytoplasm and nucleus of articular chondrocytes were blindly quantified with MetaMorph software (Molecular Devices, LLC). When the intensity of β-catenin in the nucleus was similar to or more than that in the cytoplasm, the cell was recognized as nuclear β-catenin-positive.
Statistical analysis. All continuous variables are expressed as mean ± standard deviation (SD). Statistical significance was estimated either by Student's t-test or one-way ANOVA followed by Tukey's post-hoc test. P-values less than 0.05 was considered statistically significant. All statistical analyses were performed with SPSS ver. 23 (IBM Corp.).
Other Materials and Methods. Details of other materials and methods are available in the Supplementary
Information. This section includes detailed descriptions of total RNA extraction, real-time quantitative polymerase chain reaction (qPCR), Alcian blue staining, MTS assay, and isolation of human osteoarthritic chondrocyte (OAC) cells. cellular area and the DAPI-positive nuclear area are normalized to the number of cells and also to that in total cellular area in PBS-treated cartilage. **P < 0.01 by one-way ANOVA followed by Tukey's post-hoc test. Mean and SD are indicated (n = 3 knees in each group). (F) The number of β-catenin-positive cells is divided by the number of DAPI signals to calculate the ratio of nuclear β-catenin-positive cells. The number of β-cateninpositive cells is divided by the number of DAPI signals to calculate the ratio of nuclear β-catenin-positive cells. *P < 0.05 by one-way ANOVA followed by Tukey's post-hoc test. Scale bar = 200 μm (A), 100 µm (C), and 25 µm (D). (G) Model of Rspo2-mediated OA development, and the effect of mianserin.
